Advertisement
Advertisement
U.S. markets open in 4 hours 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

MiNK Therapeutics, Inc. (INKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
1.3300+0.0400 (+3.10%)
At close: 03:59PM EDT
1.3400 +0.01 (+0.75%)
After hours: 07:47PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
Previous Close1.2900
Open1.3100
Bid1.2300 x 3000
Ask1.5100 x 800
Day's Range1.2600 - 1.3800
52 Week Range0.8510 - 3.4200
Volume18,849
Avg. Volume82,926
Market Cap45.896M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings DateNov 03, 2023 - Nov 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INKT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MiNK Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/22/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    MiNK Therapeutics to Participate in September Investor Conferences

    NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences: Baird 2023 Global Healthcare Conferenc

  • GlobeNewswire

    MiNK Therapeutics Reports Second Quarter 2023 Results

    - Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress - MiNK-215, a Novel FAP-CAR-iNKT Cell Therapy, Eliminated Tumors in NSCLC Models NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer

  • GlobeNewswire

    MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

    Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release befo

Advertisement
Advertisement